



Embrace Changes and Mitigate Legal Risks Associated with Opioid Prescribing and the Issue of Overdose:

An Updated Blueprint for the Frontline Pain Practitioner and Medical Directors

Created and presented by:
Jennifer Bolen, JD

Disclosures for Jennifer Bolen, JD



- Consultant - Generation Partners
- Consultant - Abbott/Alere Toxicology
- Consultant - MTL Solutions, LLC
- Consultant - MyMOMD
- Consultant - Paradigm Labs
- Consultant - Pernix Therapeutics
- Consultant - ReCept Pharmacy
- Consultant - Westox Labs

Copyright 2018, The J. Bolen Group, LLC. All rights reserved.

Learning Objectives


Identify	Identify common trends in legal actions against prescribers when a patient overdoses and dies
Describe	Describe critical perspectives around a proper response to the licensing board's request for the chart and a summary of care.
List	List three common risk mitigation weaknesses associated with chronic opioid therapy
Explain	Explain how to create an action plan for changing how clinicians address the same with their staff and patients addressing these in daily practice and medical record documentation.
Discuss	Discuss case examples using a before and after application of the three pronged risk mitigation improvement plan.

Copyright 2016-2018, The J. Bolen Group, LLC. All rights reserved.

OBJECTIVES 1 and 2:

1. Identify Common Trends in Legal Actions against a Prescriber when a Patient Overdoses and Dies.

2. Describe Critical Perspectives Around the Licensing Board's Request for the chart and a Summary of Care



Dear Pain Management Practitioner: • Love, Your licensing board • PS: You have 21 days to do this!	This office is in receipt of only one version of the allegations contained in the enclosed information is being submitted to you to provide you the opportunity recollection of the incident. Therefore, please submit a narrative setting forth and response to the allegations contained in the complaint. Your response to also include copies of all relevant medical treatment records, pursuant to
--	---

The typical case goes something like this . . .	<table border="1"> <tr> <td style="width: 15%; text-align: center;">Get</td> <td> Get Letter •Hit the Panic Button •Reality Sets in </td> </tr> <tr> <td style="text-align: center;">Talk</td> <td> Talk to Lawyer •Gather Files; Hit Panic Button •Denial takes hold, with Anger as a seat buddy </td> </tr> <tr> <td style="text-align: center;">Make</td> <td> Make a Choice •Approach with Confidence and Send in Fact-Filled, Humble Response; Fight if you have to •OR Continue Denial and Fight without a helpful framework </td> </tr> </table>	Get	Get Letter •Hit the Panic Button •Reality Sets in	Talk	Talk to Lawyer •Gather Files; Hit Panic Button •Denial takes hold, with Anger as a seat buddy	Make	Make a Choice •Approach with Confidence and Send in Fact-Filled, Humble Response; Fight if you have to •OR Continue Denial and Fight without a helpful framework
Get	Get Letter •Hit the Panic Button •Reality Sets in						
Talk	Talk to Lawyer •Gather Files; Hit Panic Button •Denial takes hold, with Anger as a seat buddy						
Make	Make a Choice •Approach with Confidence and Send in Fact-Filled, Humble Response; Fight if you have to •OR Continue Denial and Fight without a helpful framework						

Necessary
framework
and path
forward

Freeze	Freeze Records • Copy and Review • NOTE THE FACTS; Avoid Opinion at First
Match	Match Facts Against Standards • Evaluate Strengths and Weaknesses • Identify potential expert support
Prepare	Prepare Response* (assuming advice of counsel is to do this) • Carefully mix case facts with humble description of decision-making • Wait and see, but prepare for possible next steps

Licensing Board Inquiry – Understand Perspectives (and the playing field)		
What the Board sees through the eyes of the complainant	What you see (and think) when confronted with a Board letter	Reconciling the realities and embracing necessary changes/updates to your program
Someone has died	What? Why didn't they tell me sooner?	
You were prescribing them opioids and other medication	Yes, they were in pain.	What is in your charts that shows your rationale for each medication?
They died within a week or so of getting their last prescription from you	What? Why didn't they tell me sooner?	What type of risk monitoring were you doing? Did anything slip through the cracks? UDT Timing? Risk Status? Coordination of Care?
The complainant is a family member who knows the person who died and the story is compelling	Uh-oh.	Did you have prior contact with the family member? Anything in writing? How about patient education?
The complainant usually articulates facts that you either didn't know, didn't fully explore, or ignored. The Board wants to see the story your records tell.	1. No one told me. 2. They told me, but I didn't respond. 3. They told me, but my lawyer said not to respond. 4. I did everything right.	Do your records speak for you?
The board wants a full explanation. You have important legal rights, but the board is watching how you handle your response.	My attorney will solve everything. Right?!	Does your attorney speak pain? Do you need experts? The answer depends on many things.

If you have done your job . . . Then maybe


I am reporting to you the results of the review by the [SOME STATE] Board of Medical Examiners (the “Board”) of the complaint filed regarding the above-referenced individual. In the course of the inquiry, the Board considered your response.

The Board has completed its review of the facts related to this matter and has determined that the issues identified were distressing to the complainant, but do not provide any basis to initiate disciplinary action.

The Board initiated this review because of its duty to safeguard the public by assuring that you, as a physician licensed to practice in this State, are complying with applicable statutes, regulations, and accepted standards of practice. As such, this matter is administratively closed.

This disposition of the complaint is being placed in the confidential files of the Board. Please be aware that, within this context, the complainant will be appropriately advised of the Board’s handling of this matter.

What questions does the licensing board investigator try to answer? – Critical Perspectives



- **Does the record show that the Practitioner Issue a Controlled Substance Prescription:**
 - With or Without a proper evaluation, including proper risk assessment, and did he/she arrive at a diagnosis and create a treatment plan with goals and measurable milestones?
 - With or Without ongoing evaluation and risk mitigation, including timely use of the state’s PDMP, UDT results, naloxone, and other control measures?
 - With or Without the proper documentation, including rationale for starting, changing, not stopping opioids; Is the rationale for the prescribed drugs clearly stated in the medical record?
 - With or Without Coordinating Care?

Copyright 2016-2018, The J. Bolen Group, LLC. All rights reserved.

Reminder: Core Responsibilities when Prescribing Controlled Substances

DEA Standards

Licensing Board Standards

Position of Trust over the Patient

Copyright 2016-2018, The J. Bolen Group, LLC. All rights reserved.

DEA “Standards”
for Registrants
who Prescribe
Controlled
Substances

Legitimate Medical Purpose	One or more generally recognized medical indication for the use of the controlled substance
Usual Course of Professional Practice	According to licensing and professional standards, including consideration of licensing board material; Steps of a “Reasonably Prudent” Practitioner
Reasonable Steps to Prevent Abuse and Diversion	Proper Risk Evaluation, Stratification, and Monitoring Protocols, including overdose risk evaluation PDMP , UDT, NALOXONE, OPIOID TRIAL, VISIT FREQUENCY, Many other “reasonable steps”

Copyright 2016-2018, The J. Bolen Group, LLC. All rights reserved.

Licensing Board and Professional “Standards” and Documentation of Same

Historical Steps with Patient	Active Care Plan Steps	Coordination of Care and Consultations/Referrals
• General medical history • Pain Specific History • Risk of Abuse/Addiction • Risk of Diversion • Risk of Overdose	• Opioid Trial and Some form of Exit Strategy • Treatment Plan for Frequency, Handling MME, PDMP utilization, UDT, etc. • Naloxone and Patient Education • Documentation and Process of Informed Consent and Treatment Agreement	• Scope of Practice Issues • Exchange of documentation between PCP and Specialty providers engaged in chronic MEDICATION therapy (not just limited to opioids) • Dealing with Marijuana issues • Rationale for starting, stopping, changing, etc.

Copyright 2016-2018, The J. Bolen Group, LLC. All rights reserved.

Sample Licensing Board Guidelines/Rules

- Example is from California and a comparison between the California Pain Guidelines (2014) to the CDC Guidelines (2016)

COMPARISON OF PRESCRIBING GUIDELINES FOR CONTROLLED SUBSTANCES (OPIODS) FOR CHRONIC PAIN	
Centers for Disease Control and Prevention (CDC) Prescriber Guidelines for Chronic Pain	Medical Board of California (MBC) Prescriber Guidelines for Substances for Pain
CDC recommendations are based upon the following assessment: • No evidence of long-term benefits from opioids in pain and function for chronic pain with outcomes examined at least 3 year later. • Extensive evidence shows the possible harms of opioids (including abuse and dependence, overdose, myocardial infarction, motor vehicle crashes), and • Extensive evidence suggests benefits of alternative treatments compared with long-term opioid therapy, including nonpharmacologic therapy and nonopioid pharmacologic therapy, with less harm. These guidelines are intended for primary care physicians who are treating patients with chronic pain (i.e., pain lasting longer than three months or past the time of normal tissue healing) in outpatient settings. The recommendations are not intended as for guidance on use of opioids as part of medication-assisted treatment for opioid use disorders (i.e. for patients who are in active cancer treatment, palliative care, or end of life care). The three sections/categories below are based upon CDC recommendations. • Non-pharmacologic therapy and non-opioid pharmacologic therapy preferred for chronic pain • Before starting opioid therapy for pain, providers should establish treatment goals with all patients, including realistic goals for pain and function • Providers should not initiate opioid therapy without consideration of how therapy will be discontinued if unsuccessful • Providers should continue opioid therapy only if there is clinically meaningful improvement in pain and function that outweighs risks to patient safety	MBC's guidelines are intended to improve outcomes of patient care and to prevent overdose deaths due to opioid use. They particularly address the use of opioids in the long-term treatment of chronic pain. MBC recommendations are based upon: Special patient populations including: Emergency Departments, Urgent Care Clinics, Acute Pain, End-of-Life Pain, Cancer Pain, Older Adults, Pediatric Patients, Pregnant Women, Patients Covered by Workers' Compensation, Patients with History of Use Disorder, Psychiatric Patients, Patients Prescribed Benzodiazepines and Patients Prescribed Methadone or Buprenorphine for Treatment of a Substance Use Disorder. These guidelines are intended for all physicians practicing in California. These guidelines are not meant for the treatment of patients in hospice or palliative care settings or to treat treatment where improved function is not anticipated and pain relief is the primary goal. Emergency Departments (ED) or Urgent Care Clinics • Physicians should avoid the routine prescribing of opioid therapy for a patient with an acute exacerbation of chronic non-cancer pain seen in the ED. • If opioids are prescribed on discharge, the prescription should be for the lowest practical dose for a limited duration (e.g., 4-5 days). • The prescriber should consider the patient's risk for opioid misuse, abuse, or dependence. • The physician should, if practicable, honor existing patient-physician pain contracts/treatment agreements and consider past prescription patterns from information sources such as prescription drug monitoring programs.

Comparison of Prescribing Guidelines

Indicates differences between the guidelines

Page 1

COMPARISON OF PRESCRIBING GUIDELINES FOR CONTROLLED SUBSTANCES (OPIOIDS) FOR CHRONIC PAIN	
Centers for Disease Control and Prevention (CDC)	Medical Board of California (MBC)
Prescriber Guidelines for Chronic Pain	Prescriber Guidelines for Substantives for Pain
DETERMINING WHEN TO INITIATE OR CONTINUE OPIOIDS for CHRONIC PAIN (Continued)	
- Before starting and periodically during patient treatment, providers should discuss with patients known risks and health benefits. - Discuss patient and provider responsibilities for managing therapy.	- Before starting and periodically during patient treatment, providers should discuss with patients known risks and health benefits. - Discuss patient and provider responsibilities for managing therapy.
OPIOID SELECTION, DOSAGE, DURATION, FOLLOW-UP, and DISCONTINUATION	
- When starting opioid therapy for chronic pain, providers should give the lowest effective dose of immediate-release opioid agonist. - When opioids are started, providers should provide the basis of their clinical judgment. - Providers should use caution when prescribing opioids to any patient. Providers should use caution when prescribing opioids to patients with a history of substance use disorder, mental illness, or other conditions that may increase the risk of adverse effects. - When opioids are used for moderate to severe pain, providers should provide the lowest effective dose of immediate-release opioid agonist and should consider no greater quantity than needed for the expected duration of pain, even through to repeat doses. - Types of opioid dose could be sufficient for most patients; however, some patients may need to be monitored. - Providers should consider benefits and risks of opioid therapy with patients early in therapy to assess frequency.	- When starting opioid therapy for chronic pain, providers should give the lowest effective dose of immediate-release opioid agonist. - When opioids are started, providers should provide the basis of their clinical judgment. - Providers should use caution when prescribing opioids to any patient. Providers should use caution when prescribing opioids to patients with a history of substance use disorder, mental illness, or other conditions that may increase the risk of adverse effects. - When opioids are used for moderate to severe pain, providers should provide the lowest effective dose of immediate-release opioid agonist and should consider no greater quantity than needed for the expected duration of pain, even through to repeat doses. - Types of opioid dose could be sufficient for most patients; however, some patients may need to be monitored. - Providers should consider benefits and risks of opioid therapy with patients early in therapy to assess frequency.

COMPARISON OF PRESCRIBING GUIDELINES FOR CONTROLLED SUBSTANCES (OPIOIDS) FOR CHRONIC PAIN	
Centers for Disease Control and Prevention (CDC)	Medical Board of California (MBC)
Prescriber Guidelines for Chronic Pain	Prescriber Guidelines for Substantives for Pain
DETERMINING WHEN TO INITIATE OR CONTINUE OPIOIDS for CHRONIC PAIN (Continued)	
- Before starting and periodically during patient treatment, providers should discuss with patients known risks and health benefits. - Discuss patient and provider responsibilities for managing therapy.	- Before starting and periodically during patient treatment, providers should discuss with patients known risks and health benefits. - Discuss patient and provider responsibilities for managing therapy.
OPIOID SELECTION, DOSAGE, DURATION, FOLLOW-UP, and DISCONTINUATION	
- When starting opioid therapy for chronic pain, providers should give the lowest effective dose of immediate-release opioid agonist. - When opioids are started, providers should provide the basis of their clinical judgment. - Providers should use caution when prescribing opioids to any patient. Providers should use caution when prescribing opioids to patients with a history of substance use disorder, mental illness, or other conditions that may increase the risk of adverse effects. - When opioids are used for moderate to severe pain, providers should provide the lowest effective dose of immediate-release opioid agonist and should consider no greater quantity than needed for the expected duration of pain, even through to repeat doses. - Types of opioid dose could be sufficient for most patients; however, some patients may need to be monitored. - Providers should consider benefits and risks of opioid therapy with patients early in therapy to assess frequency.	- When starting opioid therapy for chronic pain, providers should give the lowest effective dose of immediate-release opioid agonist. - When opioids are started, providers should provide the basis of their clinical judgment. - Providers should use caution when prescribing opioids to any patient. Providers should use caution when prescribing opioids to patients with a history of substance use disorder, mental illness, or other conditions that may increase the risk of adverse effects. - When opioids are used for moderate to severe pain, providers should provide the lowest effective dose of immediate-release opioid agonist and should consider no greater quantity than needed for the expected duration of pain, even through to repeat doses. - Types of opioid dose could be sufficient for most patients; however, some patients may need to be monitored. - Providers should consider benefits and risks of opioid therapy with patients early in therapy to assess frequency.

California Comparison Continued

OBJECTIVES 3 and 4:


3. List three common risk mitigation weaknesses associated with chronic opioid therapy

4. Create an action plan for changing how clinicians address the same with their staff and patients addressing these in daily practice and medical record documentation.



LEGAL PERSPECTIVE:

Three common risk mitigation weaknesses associated with chronic opioid therapy



Recent Clinical Literature
Examining Potentially
Inappropriate Prescribing
Behavior and Connection
to Overdose and
Mortality

A QUICK PUB MED SEARCH

1. [Potentially Inappropriate Opioid Prescribing, Overdose, and Mortality in Massachusetts, 2011-2015.](#)
Rose AJ, Bernson D, Chui KKH, Land T, Walley AY, LaRoche MR, Stein BD, Stopka TJ.
J Gen Intern Med. 2018 Jun 14. doi: 10.1007/s11606-018-4532-5. [Epub ahead of print]
PMID: 29948815
[Similar articles](#)
2. [Controlled Substance Prescribing Patterns—Prescription Behavior Surveillance System, Eight States, 2013.](#)
Paulozzi LJ, Strickler GK, Kreiner PW, Koris CM; Centers for Disease Control and Prevention (CDC).
MMWR Surveill Summ. 2015 Oct 16;64(9):1-14. doi: 10.15585/mmwr.ssr6409a1.
PMID: 26469747
[Similar articles](#)
3. [Patterns of Opioid Use and Risk of Opioid Overdose Death Among Medicaid Patients.](#)
Garg RK, Fulton-Kehoe D, Franklin GM.
Med Care. 2017 Jul;55(7):e61-e68. doi: 10.1097/MLR.0000000000000738.
PMID: 28614178
[Similar articles](#)
4. [High-risk use by patients prescribed opioids for pain and its role in overdose deaths.](#)
Gwira Baumbatt JA, Wiedeman C, Dunn JR, Schaffner W, Paulozzi LJ, Jones TF.
JAMA Intern Med. 2014 May;174(5):796-801.
PMID: 24589873
[Similar articles](#)
5. [Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.](#)
LaRoche MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, Bagley SM, Liebschutz JM, Walley AY.
Ann Intern Med. 2018 Aug 7;169(3):137-145. doi: 10.7326/M17-3107. Epub 2018 Jun 19.
PMID: 29913516
[Similar articles](#)
6. [Association between opioid prescribing patterns and opioid overdose-related deaths.](#)
Bohnet AS, Valenstein M, Bair MJ, Ganoczy D, McCarthy JF, Ilgen MA, Blow FC.
JAMA. 2011 Apr 6;305(13):1315-21. doi: 10.1001/jama.2011.370.
PMID: 21467284
[Similar articles](#)

Copyright 2016-2018, The J. Bolen Group, LLC. All rights reserved.

Six Types of Potentially Inappropriate Opioid Prescribing Behaviors (PIP)

MME $\geq$ 100mg/day
in $\geq$ 3 mos.

Overlapping Opioid and Benzodiazepine Prescriptions in $\geq$ 3 mos.	$\geq$ 4 prescribers in any quarter	$\geq$ 4 dispensing pharmacies in any quarter	Cash purchase of opioid prescriptions on $\geq$ 3 occasions	Receipt of opioids in $\geq$ 3 mos. Without a documented pain diagnosis
--	-------------------------------------	---	---	---

J Gen Intern Med. 2018 Jun 14. doi: 10.1007/s11606-018-4532-5. [Epub ahead of print]

Potentially Inappropriate Opioid Prescribing, Overdose, and Mortality in Massachusetts, 2011-2015.

Rose AJ^{1,2}, Bensen D³, Chui KK⁴, Land T³, Walley AV^{5,3}, LaRochelle MR⁵, Stein BD^{6,7}, Stocka T^{4,8}.

Author Information

Abstract

BACKGROUND: Potentially inappropriate prescribing (PIP) may contribute to opioid overdose.

OBJECTIVE: To examine the association between PIP and adverse events.

DESIGN: Cohort study.

PARTICIPANTS: Three million seventy-eight thousand thirty-four individuals age $\geq$ 18, without disseminated cancer, who received prescription opioids between 2011 and 2015.

MAIN MEASURES: We defined PIP as (a) morphine equivalent dose $\geq$ 100 mg/day in $\geq$ 3 months; (b) overlapping opioid and benzodiazepine prescriptions in $\geq$ 3 months; (c) $\geq$ 4 opioid prescribers in any quarter; (d) $\geq$ 4 opioid-dispensing pharmacies in any quarter; (e) cash purchase of prescription opioids on $\geq$ 3 occasions; and (f) receipt of opioids in 3 consecutive months without a documented pain diagnosis. We used Cox proportional hazards models to identify PIP practices associated with non-fatal opioid overdose, fatal opioid overdose, and all-cause mortality, controlling for covariates.

KEY RESULTS: All six types of PIP were associated with higher adjusted hazard for all-cause mortality, four of six with non-fatal overdose, and five of six with fatal overdose. Lacking a documented pain diagnosis was associated with non-fatal overdose (adjusted hazard ratio [AHR] 2.21, 95% confidence interval [CI] 2.02-2.41), as was high-dose opioids (AHR 1.68, 95% CI 1.59-1.76). Co-prescription of benzodiazepines was associated with fatal overdose (AHR 4.23, 95% CI 3.85-4.65). High-dose opioids were associated with all-cause mortality (AHR 2.18, 95% CI 2.14-2.23), as was lacking a documented pain diagnosis (AHR 2.05, 95% CI 2.01-2.09). Compared to those who received opioids without PIP, the hazard for fatal opioid overdose with one, two, three, and $\geq$ four PIP subtypes were 4.24, 7.05, 10.28, and 12.99 (test of linear trend, $p < 0.001$).

CONCLUSIONS: PIP was associated with higher hazard for all-cause mortality, fatal overdose, and non-fatal overdose. Our study implies the possibility of creating a risk score incorporating multiple PIP subtypes, which could be displayed to prescribers in real time.

KEYWORDS: mortality; opioids; overdose; potentially inappropriate prescribing

PMID: 29548815 DOI: 10.1007/s11606-018-4532-5


PIP Article	Bolen Group Audit Findings	General Suggestions for Improvement
MME $\geq$ 100mg/day for $\geq$ 3 mos.	Frequent failures to track MME	Track MME
Overlapping Opioid and Benzodiazepine Prescriptions in $\geq$ 3 mos.	Sometimes overlapping involves more than one opioid and more than one Benzodiazepine, along with sleep medication, muscle relaxants, etc. and rationale not documented; coordination of care missing.	1. Document rationale for combination prescribing 2. Coordinate care with BZO prescriber 3. May be appropriate to discuss reducing Benzodiazepines or limiting term of use or time of reevaluation.
$\geq$ 4 prescribers and pharmacists in any quarter	Multiple prescribers often involved people in the same practice or PCP/Internal Medicine, Pain Specialist, and Psychiatrist Multiple pharmacists happen for different reasons. Sometimes not clear in chart.	1. Use PDMP 2. Coordinate care with other physicians and pharmacists, especially for complex patient 3. Discuss need to know who treats patient and where medication is filled, what's prescribed, and why.
Cash purchase of opioids on $\geq$ 3 occasions	Didn't find in our audit	1. Outside scope of lecture
Receipt of opioids in $\geq$ 3 mos. without a documented pain diagnosis	Found mixed results on pain diagnosis. Sometimes specific diagnosis after workup. Other times, general diagnosis and failure to reevaluate after initial opioid trial period.	1. Perform a thorough evaluation 2. Document a specific diagnosis or working diagnosis 3. Evaluate frequently during first year and thereafter per standards

Comparing PIP to Our Anecdotal Audit Findings

Comparing PIP to Our Anecdotal Audit Findings - 2

PIP Article	Bolen Group Audit Findings	Remedy
NOT MENTIONED	INCONSISTENT OR LACK OF USE OF ANY RISK ASSESSMENT PLAN or SUMMARY OF FINDINGS	See Sample Tool
NOT MENTIONED	Delayed timing in review of UDT results and use of those results in treatment of patient	1. UDT Results Triage 2. Ongoing Use of UDT results in Tx 3. Documentation 4. See UDT Lecture

The mindset is to create the “cheese trail” that reflects the prescriber’s rationale at various data points



Part 2 – Meet John Smith, Jane Doe, and a Young Guy

Examining three critical areas of risk mitigation weakness
through case examples

Case Example #1 – John Smith

Patient is a 33 y/o male

He was crossing the street and got hit by a bus. Rib fractures. Collar bone fracture. Leg fracture. Spent several months in the hospital and undergoing rehabilitation.

Patient now in chronic pain.

Rx opioids. Rx benzodiazepines. Occasional Rx antidepressant use.

Patient has a history of drinking and smoking.

Patient has a history of aberrant drug related behaviors, including use of diphenhydramine and trazodone.

Patient has a very high SOAPP-R score (high risk).

John Smith's Risk Assessment History

DATA POINT	Initial OV	6 months in	1 year in	Month of OD
SOAPP/Psych Testing	High risk Depression Scale	SOAPP scores 12 (high risk)	Still high risk	SOAPP-R last OV
Anxiety	Reports anxiety	Reports anxiety	Anxiety not reported/documented	Suffering from insomnia, panic attacks, anxiousness/stress
Depression	Reports feeling more sad than usual (depressed)	Patient has psych history of depression documented, and reports feeling more sad than usual (depressed)	Continues to see a psychologist	Receiving 3 forms of antidepressant. Patient reports depression
Use of Diphenhydramine	Positive in UDS on second visit	Positive in UDS at 6 months	Positive in UDS at 18 months	Positive in last UDS
Multiple Opioids	Fentanyl and Hydromorphone	Fentanyl and Hydromorphone	Fentanyl and Hydromorphone	Fentanyl and Oxycodone
Use of Benzodiazepines	Taking 1mg Alprazolam BID	Same	Oxazepam appears in UDS along with Alprazolam	Afraid will run out of Alprazolam because prescribing provider unavailable
Smoker	Current every day smoker- 1 PPD	Current every day smoker	Reported as a former smoker, but Cotinine continues to appear positive in UDS	Reported as former smoker
Drinker	Patient drinks 1-13 alcoholic beverages per month	Reported to drink 1-13 alcoholic beverages a month- Alcohol in UDS	Reported as non drinker	Patient reports alcohol abuse- not counseled
MME	267mg MME	267mg MME	216mg MME	180mg MME

Opioid Dose Calculator <http://www.agencymeddirectors.wa.gov/calculator/dosecalculator.htm>

Opioid Dose Calculator

Instructions: Fill in the mg per day* for whichever opioids your patient is taking. The web page will automatically calculate the total morphine equivalents per day.

Patient's Name: John Smith
Today's Date: August 24, 2018

Opioid (oral or transdermal): **mg per day:*** **Morphine equivalents:**

Codine 0

Fentanyl transdermal (in mcg/hr) 75 180

Hydrocodone 0

Hydromorphone 24 96

Methadone† 0

Morphine 0

Oxycodone 0

Oxymorphone 0

Tapentadol 0

Tramadol 0

Total **276**

John Smith – Initial MME

- 75 mcg/day Fentanyl
- 4mg hydromorphone, #6 per day

John Smith's Last Office Visit 3/9/18

- Complained of anxiety, lack of sleep, pain, and alcohol troubles.
- Concerned about running out of alprazolam because his prescribing physician is not available.
- During visit, provider:
 - Rx FENTANYL, 50mcg Q72 = 120 mg MME
 - Rx Oxycodone, 10mg Q6 hours (40mg) = 60mg MME
 - Rx Alprazolam to keep patient from having seizures; supply covers 7 days (1 tablet BID)
- Total MME is 180mg/day
- Requested Drug Test
- Updated SOAPP-R
- Patient's BP was 88/64

John Smith's Last Risk Assessment Responses Mar. 9, 2018

SOAPP - R Mar. 9, 2018

The following are some questions given to patients who are on or being considered for medication for their pain. Please answer each question as honestly as possible. There are no right or wrong answers.

JOHN SMITH	NEVER 0	SELDOM 1	SOMETIMES 2	OFTEN 3	VERY OFTEN 4
1. How often do you have mood swings?					✓
2. How often have you felt a need for higher doses of medication to treat your pain?					✓
3. How often have you felt impatient with your doctors?		✓			
4. How often have you felt that things are just too overwhelming that you can't handle them?					✓
5. How often is there tension in the home?					✓
6. How often have you counted pain pills to see how many are remaining?					✓
7. How often have you been concerned that people will judge you for taking pain medication?					✓
8. How often do you feel bored?					✓
9. How often have you taken more pain medication than you were supposed to?					✓
10. How often have you worried about being left alone?				✓	
11. How often have you felt a craving for medication?					✓
12. How often have others expressed concern over your use of medication?					✓
13. How often have any of your close friends had a problem with alcohol or drugs?	✓				

©2007 Intuitive, Inc. All rights reserved. 100 Broadway Street, Suite 300, New York, NY 10038
Phone 857-532-9228 Fax 857-532-9821 Email info@intuitive.com
The SOAPP-R and SOAPP-R for patients with pain was developed with
a grant from the National Institutes of Health (R01DA023353-01A1).

John Smith

	NEVER 0	SELDOM 1	SOMETIMES 2	OFTEN 3	VERY OFTEN 4
14. How often have others told you that you had a bad temper?					✓
15. How often have you felt consumed by the need to get pain medication?				✓	all the time
16. How often have you run out of pain medication early?					
17. How often have others kept you from getting what you deserve?					
18. How often, in your lifetime, have you had legal problems or been arrested?	✓				
19. How often have you attended an AA or NA meeting?	✓				
20. How often have you been in an argument that was so out of control that someone got hurt?	✓				
21. How often have you been sexually abused?	✓				
22. How often have others suggested that you have a drug or alcohol problem?	✓				
23. How often have you had to borrow pain medications from your family or friends?	✓				
24. How often have you been treated for an alcohol or drug problem?	✓				

John Smith's Drug Test Results – Timing and Utility

Assession Collection Date	Test 5 3/09/18	Test 4 1/12/18	Test 3 12/14/17	Test 2 10/11/17	Test 1 9/13/17	
Drug						
Oxycodone	25	100	190	219	245	
Oxycodone	Not Detected	Not Detected	Not Detected	110	Not Detected	
Alprazolam	Not Detected	299	367	371	219	
Alprazolam	Not Detected	2121	>2778	1850	1159	RX MED*
Tramadol/acetaminophen	1565	Not Detected	Not Detected	Not Detected	Not Detected	
Alcohol, Ethyl	0.179	Not Detected	Not Detected	Not Detected	Not Detected	
Hydrocodone	Not Detected	>10000	4411	>4567	>4062	
Oxycodone	1970	Not Detected	Not Detected	Not Detected	Not Detected	RX MED in 3/18 (not prior)
Oxycodone	504	Not Detected	Not Detected	Not Detected	Not Detected	
Noroxycodone	7457	Not Detected	Not Detected	Not Detected	Not Detected	
Noroxycodone	309	Not Detected	Not Detected	Not Detected	Not Detected	
Fentanyl	35	8	8	14	11	RX MED
Norfenitanyl	674	344	239	418	188	
Tramadol	Not Detected	PRESENT	Not Detected	Not Detected	Not Detected	
O-Desmethylnaloxone	Not Detected	PRESENT	Not Detected	Not Detected	Not Detected	
N-Desmethylnaloxone	Not Detected	PRESENT	Not Detected	Not Detected	Not Detected	
Traxidone	Not Detected	PRESENT	Not Detected	PRESENT	PRESENT	
1,3 dioxolene piperazine	PRESENT	PRESENT	PRESENT	PRESENT	PRESENT	
Ibuprofen	Not Detected	PRESENT	PRESENT	PRESENT	PRESENT	
Naproxen	PRESENT	Not Detected	Not Detected	Not Detected	Not Detected	
Diphenhydramine	PRESENT	PRESENT	Not Detected	Not Detected	Not Detected	

Test results received 3/12/18

Patient overdosed 3/18/18

Test results not reviewed until after patient's death

Legend: ■ Present and Not Declared ▲ Absent but Declared ● Drugs Present, No Medication List Provided

John Smith's Last UDT Timeline

LAST OV
and UDT
SAMPLE

• Mar. 9, 2018

LAST UDT
REPORT

• Mar. 12, 2018

Patient
Overdosed
and died

• Mar. 18, 2018

SAMPLE STATE RULE ON USE OF DRUG TEST RESULTS (INDIANA)


STANDARDS OF PROFESSIONAL CONDUCT AND COMPETENT PRACTICE OF MEDICINE

listed in subsection (b) if the physician reasonably determines following a review of less than all of the factors listed in subsection (b) that a drug monitoring test is medically necessary.

➔ (d) Nothing about subsection (b) shall be construed to prohibit the physician from performing or ordering a drug monitoring test at any other time the physician considers appropriate.

(e) If a test performed under subsection (a), or conducted under subsection (d), reveals inconsistent medication use patterns or the presence of illicit substances, a review of the current treatment plan shall be required. Documentation of the revised treatment plan and discussion with the patient must be recorded in the patient's chart. *(Medical Licensing Board of Indiana; 844 IAC 5-6-8; filed Oct 7, 2014, 12:27 p.m.: 20141105-IR-844140289FRA, eff Nov 1, 2014 [IC 4-22-2-36 suspends the effectiveness of a rule document for 30 days after filing with the Publisher. LSA Document #14-289 was filed Oct 7, 2014.]; filed Aug 22, 2016, 11:30 a.m.: 20160921-IR-844150415FRA)*

Case Example #2 – Meet Jane Doe



CASE STUDY #2 – JANE DOE – UDT Summary

INITIAL OFFICE VISIT and RELEVANT RX	UDT ORDERED	DATE ON LAB REPORT	Date EMR Shows Review	RESULTS	Aberrant?
1/24/15 RX after OV = OXYCODONE Patient had prior Rx Tylenol #3	Yes	1/28/15	2/24/15	Gabapentin+ TCA+	Yes, Gabapentin not disclosed, but is Rx from another doctor. Oxycodone Rx given.
2/24/15 Rx is OXYCODONE, Morphine added	Yes	3/1/15	3/24/15	Gabapentin+ Oxycodone - TCA+ Dextromethorphan+	Yes, Dextromethorphan; Missing Rx Opioid (Oxy)
3/24/15 Rxs for Oxycodone, Morphine, Gabapentin	Yes	4/2/15	4/24/15	Morphine + Gabapentin+ Oxycodone +	Yes, Morphine+ but 6-MAM-NEG Oxycodone+
4/24/15 Rxs for Oxycodone, Morphine, Gabapentin	Yes	5/26/1	Reviewed after Patient's death.	Morphine+ 6-MAM+ FENTANYL+ Oxycodone+	Patient overdosed and died.

Case Example #3 – Just a young guy

Patient is a 33 y/o male

Adopted. Birth mother was an alcoholic. Served in the Marines. Combat in Iraq. Married and recently divorced.

Patient fell off of orphanage roof in early years – fractured spine; unrepaired. Injured in Iraq. Six surgeries since ended tour of duty, including hip replacement. Needs spine surgery. PTSD diagnosis. Liver damage. Necrotizing fasciitis.

Rx opioids – start and DC opioids off and on through care, as add naltrexone. Cannot tolerate Buprenorphine. Rx multiple psychiatric medications. Rx sleep medication. Rx Gabapentin. Multiple suicide attempts.

Patient has a history of smoking but now uses chewing tobacco. Prescribed an inhaler.

Patient prescribed naltrexone tablets and Gabapentin (high dose). NSAIDs for pain.

Patient recently back from alcohol rehabilitation. Continued treatment with pain practitioner's office during rehabilitation for psychiatric and pain management.

Specimen Validity - Validity Test Panel

Oxidants	NORMAL	0.0	0 - 200
pH	NORMAL	5.6	4.7 - 7.8
Specific Gravity	NORMAL	1.015	1.003 - 1.035
Creatinine	NORMAL	147.5 mg/dL	20 - 200 mg/dL

Tested For	Result	Quantitation	Normalization (ng/mL)	Outcome	Cutoff	History
Alcohol Biomarkers						
Ethyl Glucuronide	Positive	> 7500 ng/mL		INCONSISTENT	500 ng/mL	
Detection Window 1-2 days. Ethyl glucuronide (EtG) is a metabolite of ethanol (ethyl alcohol). Due to its longer detection time, EtG may be present in the absence of ethyl sulfate (EtS).						
Ethyl Sulfate	Positive	2191 ng/mL		INCONSISTENT	200 ng/mL	
Detection Window 2-3 days. Ethyl sulfate (EtS) is a metabolite of ethanol (ethyl alcohol) and its presence is specific for recent ethanol use. EtS has a shorter half-life than Ethyl glucuronide (EtG).						

Antidepressants, not otherwise specified

Bupropion	Negative				100 ng/mL	
Desmethylvenlafaxine	Positive	> 750 ng/mL		INCONSISTENT	50 ng/mL	
Detection Window 1-2 days. Desmethylvenlafaxine, or desvenlafaxine, is an antidepressant prescribed as Pristiq. It is also the metabolite of the antidepressant venlafaxine (Effexor).						
Hydroxybupropion	Negative				100 ng/mL	
Venlafaxine	Positive	1226 ng/mL		INCONSISTENT	100 ng/mL	
Detection Window 1-2 days. Venlafaxine is an antidepressant prescribed as Effexor. Its metabolite, desmethylvenlafaxine is also a prescribed antidepressant (Pristiq)						

Antipsychotics

9-Hydroxyrisperidone	Negative				100 ng/mL	
Norquetiapine	Positive	394 ng/mL		INCONSISTENT	100 ng/mL	
Detection Window 1-2 days. Active metabolite of Quetiapine (Ketiopin, Quepin, Seroquel). Quetiapine is a prescribed dibenzothiazepine derivative that has been clinically used as a neuroleptic agent in the treatment of psychosis.						


Substance	Result	Cutoff	Interpretation	Limit
Opiates				
Codeine	Positive	550 ng/mL	INCONSISTENT	50 ng/mL
Detection Window 1-2 days. Codeine is an opiate with many therapeutic uses. Codeine is metabolized into morphine, and trace amounts of hydrocodone.				
Dihydrocodeine	Negative			50 ng/mL
Hydrocodone	Positive	531 ng/mL	INCONSISTENT	50 ng/mL
Detection Window 1-2 days. Hydrocodone is a semi-synthetic opioid analgesic. It metabolizes into Dihydrocodeine, norhydrocodone, and hydromorphone. Preparations include Vicodin, Lortab and Norco.				
Hydromorphone	Negative			50 ng/mL
Morphine	Positive	> 750 ng/mL	INCONSISTENT	50 ng/mL
Detection Window 1-2 days. The presence of Morphine has been confirmed. Possible sources can include (but are not limited to) Morphine drugs, Codeine metabolism, or Heroin Metabolism.				
Norhydrocodone	Negative			50 ng/mL

Substance	Result	Cutoff	Interpretation	Limit
Fentanyl				
Carfentanil	Negative			1 ng/mL
Fentanyl	Negative			2 ng/mL
Norfentanyl	Negative			8 ng/mL
Gabapentin				
Gabapentin	Positive	> 15000 ng/mL	INCONSISTENT	1000 ng/mL
Detection Window 1-2 days. Gabapentin, a GABA analog, is marketed under the brand name Neurontin.				
Heroin Metabolite				
6-MAM	Positive	> 375 ng/mL	INCONSISTENT	25 ng/mL
Detection Window up to 1 day. 6-MAM is a unique metabolite of the illicit drug heroin. The presence of 6-MAM has been confirmed and indicates recent heroin usage.				

OBJECTIVES 4 and 5:

4. Create an action plan for changing how clinicians address the same with their staff and patients addressing these in daily practice and medical record documentation.

5. Discuss case examples using a before and after application of the three pronged risk mitigation improvement plan.



Do you prescribe opioids and/or benzodiazepines?

Do you have patients with medical co-morbidities, such as sleep apnea, asthma?


Do you have patients on more than 90mg MME?

Do you have patients with substance abuse histories, including ETOH, 6-AM, and THC?


Do you have patients with psychiatric disorders, including PTSD?

Do you have patients who have been discharged from other practices because of aberrant, drug-related behavior?

START HERE → Ask yourself these questions (and more)




Step 1 – Select Three Charts to Review



Copyright 2016-2018, The J. Bolen Group, LLC. All rights reserved.

Step 2 – Make a List of Licensing Board and Professional Standards “Directives”



Copyright 2016-2018, The J. Bolen Group, LLC. All rights reserved.

INDIANA RULE – EVALUATION AND RISK STRATIFICATION

844 IAC 5-6-4 Evaluation and risk stratification by physician

Authority: IC 25-22.5-2-7; IC 25-22.5-13-2

Affected: IC 25-1-9; IC 25-22.5

Sec. 4. (a) The physician shall do the physician's own evaluation and risk stratification of the patient by doing the following in the initial evaluation of the patient:

- (1) Performing an appropriately focused history and physical exam and obtain or order appropriate tests, as indicated.
- (2) Making a diligent effort to obtain and review records from previous health care providers to supplement the physician's understanding of the patient's chronic pain problem, including past treatments, and documenting this effort.
- (3) Asking the patient to complete an objective pain assessment tool to document and better understand the patient's specific pain concerns.
- (4) Assessing both the patient's mental health status and risk for substance abuse using available validated screening tools.
- (5) After completing the initial evaluation, establishing a working diagnosis and tailoring a treatment plan to meaningful and functional goals with the patient reviewing them from time to time.

(b) Where medically appropriate, the physician shall utilize nonopioid options instead of or in addition to prescribing opioids.

(Medical Licensing Board of Indiana; 844 IAC 5-6-4; filed Oct 7, 2014, 12:27 p.m.: 20141105-IR-844140289FRA, eff Nov 1, 2014 [IC 4-22-2-36 suspends the effectiveness of a rule document for 30 days after filing with the Publisher. LSA Document #14-289 was filed Oct 7, 2014.])

CDC Opioid Prescribing Guidelines - Checklist

Checklist for prescribing opioids for chronic pain

For primary care providers treating adults (18+) with chronic pain > 3 months, excluding cancer, palliative, and end-of-life care

GOALS

When CONSIDERING long-term opioid therapy

- Set realistic goals for pain and function based on diagnosis (eg, walk around the block).
- Check that non-opioid therapies tried and optimized.
- Discuss benefits and risks (eg, addiction, overdose) with patient.
- Evaluate risk of harm or misuse.
 - Discuss risk factors with patient.
 - Check prescription drug monitoring program (PDMP) data.
 - Check urine drug screen.
- Set criteria for stopping or continuing opioids.
- Assess baseline pain and function (eg, PEG scale).
- Schedule initial reassessment within 1–4 weeks.
- Prescribe short-acting opioids using lowest dosage on product labeling; match duration to scheduled reassessment.

If RENEWING without patient visit

- Check that return visit is scheduled < 3 months from last visit.

When REASSESSING at return visit

Continue opioids only after confirming clinically meaningful improvements in pain and function without significant risks or harm.

- Assess pain and function (eg, PEG); compare results to baseline.
- Evaluate risk of harm or misuse.
 - Observe patient for signs of over-sedation or overdose risk.
 - If yes: Taper dose.
 - Check PDMP.
 - Check for opioid use disorder if indicated (eg, difficulty controlling use).
 - If yes: Refer for treatment.
- Check that non-opioid therapies optimized.
- Determine whether to continue, adjust, taper, or stop opioids.
- Calculate opioid dosage morphine milligram equivalent (MME).
 - If < 50 MME/day total (< 50 mg hydrocodone, < 23 mg oxycodone), increase frequency of follow-up; consider offering naloxone.
 - Avoid > 90 MME/day total (> 90 mg hydrocodone, > 60 mg oxycodone), or carefully justify; consider specialist referral.
- Schedule reassessment at regular intervals (< 3 months).

NOTES

EVIDENCE ABOUT OPIOID THERAPY

- Benefits of long-term opioid therapy for chronic pain not well supported by evidence.
- Short-term benefits small to moderate for pain; inconsistent for function.
- Insufficient evidence for long-term benefits in low-back pain, headache, and fibromyalgia.

NON-OPIOID THERAPIES

- Use alone or combined with opioids, as indicated.
- Non-opioid medications (eg, NSAIDs, TCAs, SNRIs, well-controlled).
- Physical treatments (eg, exercise therapy, weight loss).
- Behavioral treatment (eg, CBT).
- Procedures (eg, intra-articular corticosteroids).

EVALUATING RISK OF HARM OR MISUSE

- Known risk factors include:
 - Illegal drug use; prescription drug use for nonmedical reasons.
 - History of substance use disorder or overdose.
 - Mental health conditions (eg, depression, anxiety).
 - Sleep-disordered breathing.
 - Concurrent benzodiazepine use.

Use drug testing: Check to confirm presence of prescribed substances and for undisclosed prescription drug or illicit substance use.

Prescription drug monitoring program (PDMP): Check for opioids or benzodiazepines from other sources.

ASSESSING PAIN & FUNCTION USING PEG SCALE

PEG score = average of 3 individual question scores (0/10; improvement from baseline is clinically meaningful)

1. What number from 0–10 best describes your pain in the past week?
 - 0 = “no pain”; 10 = “worst you can imagine”
2. What number from 0–10 describes how, during the past week, pain has interfered with your enjoyment of life?
 - 0 = “not at all”; 10 = “complete interference”
3. What number from 0–10 describes how, during the past week, pain has interfered with your general activity?
 - 0 = “not at all”; 10 = “complete interference”



U.S. Department of Health and Human Services
Centers for Disease Control and Prevention

TO ORDER MORE:
WWW.CDC.GOV/OPRESCRIPTIONPRESCRIBINGGUIDELINE

March 2016



Step 3 –
Review Charts with
Directives List in Mind;

Ask: Where am I
vulnerable?

Copyright 2016-2018, The J. Bolen Group, LLC. All rights reserved.

Risk Evaluation and Risk Management

Turn your weaknesses into strengths and change the conversation with the patient

RISK DOMAINS CHECKLIST – FROM Argoff, et al




Figure 3 Explanations for risk factors of opioid misuse and opioid use disorder [19,97,102–107].

Rational Urine Drug Monitoring in Patients Receiving Opioids for Chronic Pain: Consensus Recommendations, by Charles E. Argoff, MD,* Daniel P. Alford, MD, MPH,† Jeffrey Fudin, PharmD, DAIPM, FCCP, FASHP,‡ et al., *Pain Medicine* 2017; 0: 1–21

Risk of Overdose
– No Universal
Standard yet, but
SAMHSA and
CDC, and Ohio

EVALUATING RISK OF HARM OR MISUSE

Known risk factors include:

- Illegal drug use; prescription drug use for nonmedical reasons.
- History of substance use disorder or overdose.
- Mental health conditions (eg, depression, anxiety).
- Sleep-disordered breathing.
- Concurrent benzodiazepine use.

RISK-Behavior Tracking Form Ideas

You cannot effectively talk with a patient about risk issues, if you do not have an overall understanding of the patient's behavioral patterns.

JBG-IP-2002-2018-RISK SIGNALS-ABERRANT BEHAVIOR CHECKLIST

INSTRUCTIONS: This document is known as an Aberrant Behavior Check List and Follow-up Record. Record this information so you can locate it easily and use it throughout your office's relationship with the patient. Each time a patient returns for a follow-up visit, and in connection with any telephone communications with the patient, caregiver, or family member, assess and document potential aberrant behaviors. Alone, or in combination, these behaviors may be suggestive of prescription drug abuse or drug diversion. Remember, aberrant behaviors can be anything that is outside the documented treatment plan.

OBSERVED CHANGES IN APPEARANCE	GENERAL RISK FACTORS
Unkempt	Drug escalation
Disheveled	High-dose MME/day (Narrow Margin MME)
Sleepy Looking	Resonance/fluorine or antidepressants with opioids
Sedation	Participant in treatment for addiction
Nervous or jittery looking	ER Opioids for acute pain or opioid-naïve patients
Swelling of face or extremities (with or without ulcers, boils, and open sores)	Methadone Rx for opioid-naïve patient
Unexplained weight gain or loss	Recent release from, or current enrollment in, an abstinence, maintenance, or detox program (not methadone or buprenorphine)
GENERAL RISK FACTORS	Sleep apnea or sleep-disordered breathing
Personal history addiction and/or opioid abuse	COPD
History of, or evidence of current substance use disorder	Competitive heart failure
History of, or current mental health disorder or psychiatric illness	Kidney or liver dysfunction
Unresolved depression/mental health disorder risk of suicide (All patients should be screened during not evaluation)	Dental or hepatic disease
Family history addiction	Painkillers from, or difficulty accessing medical care
Prescription opioid abuse	Pain from MVA
Use of common oral (OPC) medications (some contain alcohol and other CNS depressants that should not be used with alcohol)	Lack of family support
Alcohol use	Age < 65
Marijuana use	MEDICATION ISSUES
Smoker	Changes made to administration (oral and snort, snuff, and inject, etc.)
Criminal history	Unusual interest in potential abuse issues associated with medication
Receiving multiple medication regimens	Increases doses without authorization
Obtain opioid preparations such as extended release or long-acting opioids that may increase risk of overdose	Using opioid for euphoria or purposeful sedation

MEDICATION ISSUES	PSYCHOLOGICAL ISSUES
MEDICATION HOARDING	"End of the world" behavior regarding medications
USES MEDS IN RESPONSE TO STRESSORS	Manipulation issues between patient and caregiver or family member
USES MEDS TO TREAT NON-PAIN STRESSORS	Negative mood changes
Using pain medications during times when pain is less severe	Isolation
USES UNSANCTIONED MEDICATION	Concerns of unusual behaviors as identified by family members
ONLY OPIOIDS WORK	Opioid withdrawal symptoms
RELUCTANCE TO CHANGE MEDS OR LOWER DOSES DESPITE STABILIZATION OR NEGATIVE EFFECTS AND DETRIMENTAL FUNCTION	Demanding behaviors in the medical office or over the telephone
INSISTS ON IN OPIOID	Abusive behavior in the waiting room
Asks for "something for my nerves"	Abusive behavior at the pharmacy
ACTIVITY ISSUES	ACTION PLAN
REQUESTS SPECIFIC DRUGS	1. All other issues to bring them up to you
ABUSED ALCOHOL	2. Family and/or caregiver to provide support and supervision (if needed)
ABUSED ILICIT DRUGS	3. Develop and implement an action plan
CAR ACCIDENT	4. Monitor and document
ARRESTED	5. Family and/or caregiver to provide support and supervision (if needed)
SOLD OR GAVE AWAY OPIOIDS	6. Monitor and document
LOST OR STOLEN PRESCRIPTIONS/MEDS	7. Family and/or caregiver to provide support and supervision (if needed)
EARLY OR FREQUENT REFILLS	8. Monitor and document
DOCTOR SHOPPING	9. Family and/or caregiver to provide support and supervision (if needed)
RECENT CARE FOR NON-FATAL OPIOID OR POISONING	10. Monitor and document
MULTIPLE ED OR URGENT CARE VISITS	11. Family and/or caregiver to provide support and supervision (if needed)
Multiple contacts between appointments	12. Monitor and document
Weekend telephone calls to your answering service	13. Family and/or caregiver to provide support and supervision (if needed)
Missed appointments	14. Monitor and document
Shares/borrows medications from friends/family	15. Family and/or caregiver to provide support and supervision (if needed)
Fills pain medications but not maintenance medications (insistent to non-opioid pharmacotherapy)	16. Monitor and document

Proper Timing and Use of UDT Results (with or without Aberrant Behaviors)


Addressing the Weaknesses

REPRISE:

Now, how do you handle Jane Doe's UDT report?

INITIAL OFFICE VISIT and RELEVANT RX	UDT ORDERED	DATE ON LAB REPORT	Date EMR Shows Review	RESULTS	Aberrant?
1/24/15 RX after OV = OXYCODONE Patient had prior Rx Tylenol #3	Yes	1/28/15	2/24/15	Gabapentin+ TCA+	Yes, Gabapentin not disclosed, but is Rx from another doctor. Oxycodone Rx given.
2/24/15 Rx is OXYCODONE, Morphine added	Yes	3/1/15	3/24/15	Gabapentin+ Oxycodone - TCA+ Dextromethorphan+	Yes, Dextromethorphan; Missing Rx Opioid (Oxy)
3/24/15 Rxs for Oxycodone, Morphine, Gabapentin	Yes	4/2/15	4/24/15	Morphine + Gabapentin+ Oxycodone +	Yes, Morphine+ but 6-MAM-NEG Oxycodone+
4/24/15 Rxs for Oxycodone, Morphine, Gabapentin	Yes	5/26/1	Reviewed after Patient's death.	Morphine+ 6-MAM+ FENTANYL+ Oxycodone+	Patient overdosed and died.

UDT TRIAGE PROTOCOL






Sample Treatment Decisions following Risky Behaviors and Aberrant UDT Results

Risk Responses- Possibilities (some work, some do not – keep the patient at the center and document rationale)		
Discussed the behavior/result	Require more frequent visits	Require increased PDMP database checks
Require increased UDT* with caution and selectively if known risks	Implement opioid supply controls (fewer dosage units in more frequently issued prescriptions)	Propose a change of medication, dosing, formulation, etc.
Refer for substance abuse treatment	Refer for mental health evaluation	Refer to specialty service
Plan reduction in opioid dose and taper off of medication (Terminate the medication)	Buprenorphine	Withdrawal from care* (serious step and requires its own lecture)
Educate	Give more strikes (wait and see)	Other

Addressing the Weaknesses

Coordination of Care





Critical Coordination of Care Issue – I’m out of my Benzodiazepines

“My primary care physician is out of town and I’m afraid I will get sick if I have to wait for him to return to get my _____ [Opioid or Benzodiazepine or other].”

PDMP Check Shows Last Rx was indeed by the name “other” prescriber and about 30 days ago. Patient seems like he’s due for a refill and not prescribing may cause seizures or withdrawal.

WHAT IF TIME:

1. What if the patient’s “other” prescriber switched their benzodiazepine from Alprazolam to Clonazepam at the last visit, and patient is now out of Alprazolam and tells you his provider is out of town and he needs his Alprazolam?

2. What if the patient’s BP during the office visit with you this same day is 80/60?

3. What if the patient tells you that he is having trouble sleeping and thinks he has sleep apnea?


4. What if the patient tells you he is using alcohol?

What do you do? What do you document? How do you handle the patient’s request for the BZO?

Patient Risk Mitigation & Risk Education

Overdose Events (Fatal or Non-Fatal):

Steps you can take to mitigate against them AND Steps you can take when they do happen



SAMHSA
Opioid Overdose Prevention
TOOLKIT:

Facts for Community Members
Five Essential Steps for First Responders
Information for Prescribers
Safety Advice for Patients & Family Members
Recovering From Opioid Overdose

 **SAMHSA**

EDUCATE PATIENTS AND STAFF MEMBERS

- <https://store.samhsa.gov/product/Opioid-Overdose-Prevention-Toolkit-Updated-2016/All-New-Products/SMA16-4742>

Resources: Websites

CDC

<http://www.cdc.gov/drugoverdose/prescribing/providers.htm>

- Provider and patient materials, including prescribing checklists, flyers, and posters

SAMHSA

<http://www.samhsa.gov/atod/opioids>

DHMH Opioid Website

dhmh.maryland.gov/medicaid-opioid-dur



MARYLAND
DEPARTMENT OF HEALTH
& MENTAL HYGIENE

Step 4A - Create a risk triage plan

Learn of Event
(see Step 4B)

Preserve Chart and
Understand Events
Regarding Specific
Patient

Obtain Legal Input
Regarding Status of
Specific Patient and
Practice Improvements
(see Step 4C)

Internal Education to
Staff and Necessary
Practice Updates

External Education to
Patients and Family
Members

Ongoing Monitoring with
Legal Counsel

Copyright 2016-2018, The J. Bolen Group, LLC. All rights reserved.

Step 4B – Identify Patients That May be at risk for Overdose Event (Fatal or Non-Fatal) and Review their Charts

Other Topic Areas for Consideration:

- Naloxone and MME
- Patient Education; **Follow-up on Naloxone Availability**
- Decisions when Patient Does not Fill Naloxone Prescription
- How you learned about the Overdose Event (Non-Fatal)
- How you learned about the Overdose Event (Fatal)
- Internal and External Responses
- Legal Issues

Copyright 2016-2018, The J. Bolen Group, LLC. All rights reserved.

Step 4C - Follow through with your plan and update it periodically

Individualized Patient Care:

1. Looks backwards and constantly reevaluates the data points

2. And moves forward with the patient's best interests in mind, carefully balancing risks and benefits

Copyright 2016-2018, The J. Bolen Group, LLC. All rights reserved.

Checklists

Licensing Board Directives	Professional Society and Basic Regulatory Guidance on Chronic Opioid Therapy	Risk Assessment Tools, Stratification, and Monitoring	Internal Education	Patient and Family Member Education
History and Physical Examination	American Academy of Pain Medicine	Risk of Abuse/Addiction	Current State Requirements	Risks of Opioid Use
Risk Evaluation	American Association for Clinical Chemistry	Risk of Diversion	CDC and Academy Positions	Informed Consent Process
Treatment Plan	Federation of State Medical Boards	Risk of Overdose	Interaction with Pharmacists	Consequences if Treatment Agreement Violation
Informed Consent	Medicare Guidance	Other Behavioral Risks	PDMP Use	Safe Use
Treatment Agreement	CDC Guidelines	Protocols for Scoring and Overall Assessment of Risk and Stratification	Drug Testing	Safe Storage
Periodic Review	SAMHSA Materials	Protocols for Monitoring tied to Risk Stratification	Opioid Trials and Exit Strategies	Safe Disposal
Consultations and Referrals	Other	Protocols for Coordination of Care	Business Relationships	Naloxone
Documentation Requirements		Referral Plan and Overdose Event Plan	Self-Audit	Exit Strategies and Boundaries

Copyright 2016-2018, The J. Bolen Group, LLC. All rights reserved.

jbolen@legalsideofpain.com

865-755-2369

Thank you!

